Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment

Diabetes ◽  
1987 ◽  
Vol 36 (1) ◽  
pp. 1-5 ◽  
Author(s):  
K. Dahl-Jorgensen ◽  
P. Torjesen ◽  
K. F. Hanssen ◽  
L. Sandvik ◽  
O. Aagenaes
Keyword(s):  
Continuous Subcutaneous Insulin Infusion ◽  
Conventional Treatment ◽  
Insulin Infusion ◽  
Insulin Antibodies ◽  
Injection Therapy ◽  
Subcutaneous Insulin ◽  
Multiple Injection

Pen injectors for insulin

1992 ◽  
Vol 30 (1) ◽  
pp. 3-4
Keyword(s):  
Continuous Subcutaneous Insulin Infusion ◽  
Multiple Dose ◽  
Insulin Infusion ◽  
Subcutaneous Insulin ◽  
Multiple Injection ◽  
Subcutaneous Injections ◽  
Acting Insulin ◽  
Short Acting Insulin ◽  
Basal Bolus ◽  
Improved Glycaemic Control

Over the last 10 years, intensified insulin regimens have been developed in the hope that improved glycaemic control will help prevent diabetic complications. The regimens involve either continuous subcutaneous insulin infusion (CSII) via a motorised pump1 or, more commonly, multiple subcutaneous injections. The multiple injection regimens usually consist of a short-acting insulin before meals with long or medium-acting insulin at bedtime (‘basal-bolus’ regimens). Pen-like injectors, which simplify the transport and injection of insulin, were developed to make these multiple dose regimens more acceptable and convenient. They are also increasingly being used with twice daily, mixed insulin regimens.

Sign in / Sign up

Export Citation Format

Share Document